## Future issues regarding aggressive extranodal lymphomas

Anatomic localization is now appreciated as a parameter for classifying diffuse large B-cell lymphomas, as exemplified by primary mediastinal large B-cell lymphoma. Of course, distinct groups of extranodal lymphomas exist, which are defined by heterogeneous presentation syndromes related to the preferentially involved organs, such as primary central nervous system lymphoma and primary testicular lymphoma, in addition to IVL. These lymphomas are consistently characterized by an aggressive clinical course and predominant or exclusive extranodal distribution, with or without mass formation and sometimes with CD5 expression, despite histological differences, such as angiotropic and intravascular patterns.[14,15] Concerning IVL, Ferreri *et al.* state, *"Extensive phenotypic and molecular characterization is needed to test whether these different clinical forms may also have different biological backgrounds, and, therefore, international co-operative studies are warranted"*. We agree with their proposal and believe that such trials should be extended to aggressive extranodal lymphomas, since there are few perspectives concerning the distinct clinicopathological profiles of such diseases or the basis of their mechanisms of lymphomagenesis, adhesion, and dissemination.[16,17]

## References

1. Gatter KC, Warnke RA. Intravascular large B-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization: Pathology and Genetics of Tumors of Heamatopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001. p. 177-8.
2. Pfleger VL, Tappeiner J. Zur Kenntnis der systemisierten Endotheliomatose der cutanen Blutgef(ass)e (Reticuloendotheliose¿). Der Hautarzt 1959;10:363-9.
3. Murase T, Nakamura S, Tashiro K, Suchi T, Hiraga J, Hayasaki N, et al. Malignant histiocytosis-like B-cell lymphoma, a distinct pathologic variant of intravascular lymphomatosis: a report of five cases and review of the literature. Br J Haematol 1997;99:656-64.
4. Murase T, Nakamura S, Kawauchi K, Matsuzaki H, Sakai C, Inaba T, et al. An Asian variant of intravascular large B-cell lymphoma: clinical, pathological and cytogenetic approaches to diffuse large B-cell lymphoma associated with haemophagocytic syndrome. Br J Haematol 2000; 111:826-34.
5. Ferreri AJ, Campo E, Seymour JF, Willemze R, Ilariucci F, Ambrosetti A, et al. Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'. Br J Haematol 2004;127:173-83.
6. Wu S-J, Chou W-C, Ko B-S, Tien H-F. Severe pulmonary complications after initial treatment with rituximab for the Asian-variant of intravascular lymphoma. Haematologica 2007;92:141-2
7. Murase T, Yamaguchi M, Suzuki R, Okamoto M, Sato Y, Tamaru JI, et al. Intravascular large B-cell lymphoma (IVL-BCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood 2007;109:478-85.
8. Majluf-Cruz A, Sosa-Camas R, Perez-Ramirez O, Rosas-Cabral A, Vargas-Vorackova F, Labardini-Mendez J. Hemophagocytic syndrome associated with hematological neoplasias. Leuk Res 1998;22:893-8.
9. Takahashi N, Chubachi A, Kume M, Hatano Y, Komatsuda A, Kawabata Y, et al. A clinical analysis of 52 adult patients with hemophagocytic syndrome: the prognostic significance of the underlying diseases. Int J Hematol 2001; 74: 209-13.
10. Dufau JP, Le Tourneau A, Molina T, Le Houcq M, Claessens YE, Rio B, et al. Intravascular large B-cell lymphoma with bone marrow involvement at presentation and haemophagocytic syndrome: two Western cases in favour of a specific variant. Histopathology 2000;37:509-12.
11. Bogomolski-Yahalom V, Lossos IS, Okun E, Sherman Y, Lossos A, Polliack A. Intravascular lymphomatosis-an indolent or aggressive entity¿ Leuk Lymphoma 1998;29: 585-93.
12. Ferreri AJM, Dognini GP, Campo E, Willemze R, Seymour JF, Bairey O, et al. Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographic regions. Hematologica 2007;92:485-91.
13. Hans CP, Weisenburger DD, Greiner TC, Gascoyne D, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-82.
14. Kanda M, Suzumiya J, Ohshima K, Tamura K, Kikuchi M. Intravascular large cell lymphoma: clinicopathological, immuno-histochemical and molecular genetic studies. Leuk Lymphoma 1999;34:569-80.
15. Yamaguchi M, Seto M, Okamoto M, Ichinohasama R, Nakamura N, Yoshino T, et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 2002;99:815-21.
16. Rubenstein JL, Fridyland J, Shen A, Aldape K, Grinzinger D, Batchelor T, et al. Gene expression and angiotropism in primary CNS lymphoma. Blood 2006;107:3176-23.
17. Ponzoni M, Arrigoni G, Gould VE, Del Curto B, Maggioni M, Scapinello A, et al. Lack of CD 29 (β1 integrin) and CD 54 (ICAM-1) adhesion molecules in intravascular lymphomatosis. Hum Pathol 2000;31:220-6.

# Prognostic analysis of aberrant somatic hypermutation of *RhoH* gene in diffuse large B cell lymphoma

Previous reports demonstrated the aberrant somatic hypermutation (SHM) of proto-oncogenes *PIM-1*, *MYC*, *RhoH* and *PAX5* as a novel mechanism of genetic lesion in diffuse large B-cell lymphoma (DLBCL).[1] The Rho family of small GTPases including Rho, Rac, and Cdc42 has been well characterized as molecular switches to transduce signals from plasma membrane to the downstream effectors. RhoH, a member of the Rho family, is specifically expressed in hematopoietic cells, especially in T and B lymphocytes, and has been reported to downregulate Rac[2] and LFA-1.[3] As RhoH is GTPase-deficient and constitutively active, GTP-bound form,[4] the activity of RhoH is directly related to the level of expression. Aberrant SHM of *RhoH* gene are distributed in intron 1 ($+300 \sim 1700$) and have been reported in 46% of DLBCL,[1] 11% of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL),[5] 11% of primary cutaneous follicular center lymphoma (PCFCL),[6] 31% of primary cutaneous large B cell lymphoma, leg type (PCLBCL),[6] and 13% of hepatitis C virus (HCV) associated non Hodgkin lymphoma.[7] Although several studies reported the SHM of DLBCL and other lymphoid malignancy, the prognostic values of SHM remain elusive. Here, we have screened for SHM of *RhoH* gene in the lymph node samples from 100 previously untreated DLBCL cases.

These patients were diagnosed and treated at Nagoya University Hospital since 1987 to 2002, and median duration of follow-up was 1026 days. Informed consent was obtained from all patients. Samples from 12 cases of reactive lymphadenopathy were also screened for negative control. Intron 1 of *RhoH* gene was amplified and screened by the denaturing HPLC (DHPLC) analysis using the WAVE Maker System (Transgenomic Inc., San Jose, CA, USA) as previously described.[8] DHPLC gradients and temperatures were determined using WAVE Maker System software. When heterozygous profiles were identified by visual inspection of the chromatograms, amplified products were cloned into pGEM-T easy vector (Promega, Madison, WI, USA) and were sequenced on the DNA sequencer (310; Applied Biosystems, Foster City, CA, USA) using the BigDye terminator cycle-sequencing kit (Applied Biosystems). Statistical analyses were performed using the Fisher exact test for $2 \times 2$ tables with StatView-J 5.5 software (Abacus Concepts Inc., Berkeley, CA, USA).

We found 78 mutations (76 point mutations, two insertions) unique to individual tumor DNAs in 35 of 100 DLBCL cases (35%) in *RhoH* gene (Table 1). Overall, 73 out of 78 were novel SHM, and five were same mutations as reported previously.[1] They shared most of the features of the immunoglobulin variable gene-associated SHM mechanism such as single nucleotide substitution ($n = 76$) with rare deletion/insertions ($n = 2$) and a predominance of transitions ($n = 48$) than transversions ($n = 28$).[5] The number of mutations in one patient ranged from 1 to 6, and 20 patients had more than one mutation. These mutations were distributed in a region throughout the first 1.6 kb of the *RhoH* gene. No mutation was detected in DNA from reactive lymphadenopathy patients except for the known polymorphism T486G in 2/12 samples.[1] The absence of

aberrant SHM tends to correlate with advanced stage (stages III and IV, $P = 0.06$), although there was no statistical significance (Table 2). The presence of aberrant SHM in *RhoH* gene impacted neither on overall survival (Figure 1a) nor disease-free survival (Figure 1b) ($P = 0.57$ and 0.75, respectively). Taken together, our study demonstrated that although the

**Table 1** Mutational analysis of *RhoH* gene in DLBCL patients

| UPN | Mutation | UPN | Mutation |
|---|---|---|---|
| 1 | C999T | 47 | G538A |
| | G1070A | | |
| | T1117A | | |
| | A1192G | | |
| 10 | A775G | 49 | A548C |
| | G798C | | G859A |
| | T1043C | | T1036A |
| | C1119T | | C1057A |
| | | | G1098T |
| | | | G1102A |
| 11 | T676C | 50 | A563C |
| | | | A591T |
| 18 | C746T | 52 | C999T |
| 22 | C505G | 53 | C1081T |
| | G1165A | | |
| 23 | T523C | 58 | C1057T |
| | G1061A | | C1062T |
| 28 | G555C | 60 | A591G |
| | G694A | | A593G |
| | G743A | | |
| | C788G | | |
| 29 | G743T | 63 | G530A |
| | G750A | | |
| | G753A | | |
| | G1012A | | |
| 31 | T412C | 67 | A721G |
| | C598T | | |
| | G1053A | | |
| | G1061A | | |
| 32 | A993T | 68 | C715T |
| | G1029C | | G817T |
| | G1084A | | ins1077T |
| | | | ins1110C |
| | | | T1127C |
| 33 | G983A | 73 | G743T |
| | T1085A | | |
| 34 | T851A | 80 | C544T |
| | | | T590G |
| 39 | C885T | 86 | C443T |
| | | | A512G |
| | | | A587C |
| 40 | T939G | 105 | C521T |
| | | | C695T |
| | | | C850G |
| | | | G1053T |
| | | | G1107T |
| | | | A1198T |
| 41 | C443T | 106 | T420C |
| | C890T | | C544T |
| 42 | G1029A | 107 | A1039C |
| 45 | G859A | 113 | T613C |
| | | | A748C |
| 46 | T814A | | |

**Table 2**  P-values of each parameter

| | Mutation (+) 35 cases (%) | Mutation (−) 65 cases (%) | P-value |
|---|---|---|---|
| Age > 60 years | 42.9 | 44.6 | 0.87 |
| Stage ≥ 3, 4 | 34.3 | 53.8 | 0.06 |
| LDH > Normal | 62.9 | 49.2 | 0.19 |
| PS ≥ 2 | 11.4 | 24.6 | 0.12 |
| Extranodal sites ≥ 2 | 22.9 | 23.1 | 0.98 |
| Male | 54.3 | 66.2 | 0.25 |



**Figure 1**    Kaplan–Meier curves according to the SHM of RhoH. (a) Overall survival in all patients. (b) Disease-free survival in all patients.

SHM might contribute to the lymphomagenesis through regulation of RhoH gene expression, it has less impact on survival of DLBCL patients.

J Hiraga[1], A Katsumi[1], T Iwasaki[1], A Abe[1], H Kiyoi[2], T Matsushita[1], T Kinoshita[1] and T Naoe[1]
[1]Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan and
[2]Department of Infectious Diseases, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
E-mail: katsumi@med.nagoya-u.ac.jp

## References

1 Pasqualucci L, Neumeister P, Goossens T, Nanjangud G, Chaganti RS, Kuppers R et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 2001; **412**: 341–346.
2 Gu Y, Jasti AC, Jansen M, Siefring JE. RhoH, a hematopoietic-specific Rho GTPase, regulates proliferation, survival, migration, and engraftment of hematopoietic progenitor cells. Blood 2005; **105**: 1467–1475.
3 Cherry LK, Li X, Schwab P, Lim B, Klickstein LB. RhoH is required to maintain the integrin LFA-1 in a nonadhesive state on lymphocytes. Nat Immunol 2004; **5**: 961–967.
4 Li X, Bu X, Lu B, Avraham H, Flavell RA, Lim B. The hematopoiesis-specific GTP-binding protein RhoH is GTPase deficient and modulates activities of other Rho GTPases by an inhibitory function. Mol Cell Biol 2002; **22**: 1158–1171.
5 Liso A, Capello D, Marafioti T, Tiacci E, Cerri M, Distler V et al. Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma. Blood 2006; **108**: 1013–1020.
6 Dijkman R, Tensen CP, Buettner M, Niedobitek G, Willemze R, Vermeer MH. Primary cutaneous follicle center lymphoma and primary cutaneous large B-cell lymphoma, leg type, are both targeted by aberrant somatic hypermutation but demonstrate differential expression of AID. Blood 2006; **107**: 4926–4929.
7 Libra M, Capello D, Gloghini A, Laura P, Berra E, Cerri M et al. Analysis of aberrant somatic hypermutation (SHM) in non-Hodgkin's lymphomas of patients with chronic HCV infection. J Pathol 2005; **206**: 87–91.
8 Kiyoi H, Yamaji S, Kojima S, Naoe T. JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults. Leukemia 2007; **21**: 574–576.

# Downregulation of microRNAs-143 and -145 in B-cell malignancies

Yukihiro Akao,[1,4] Yoshihito Nakagawa,[1] Yukio Kitade,[2] Tomohiro Kinoshita[3] and Tomoki Naoe[3]

[1]Department of Medical Oncology, Gifu International Institute of Biotechnology, 1–1 Naka-Fudogaoka, Kakamigahara, Gifu 504-0838; [2]United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Yanagido, Gifu 501-1193; [3]Department of Hematology and Oncology, Nagoya University, Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan

Recently, it has been found that inappropriate expression of microRNAs (miRNAs) is strongly associated with carcinogenesis. In this study, we demonstrated that the expression of miRNAs (miRs) -143 and -145, the levels of which were previously shown to be reduced in colon cancers and various kinds of established cancer cell lines, was also decreased in most of the B-cell malignancies examined, including chronic lymphocytic leukemias (CLL), B-cell lymphomas, Epstein-Barr virus (EBV)-transformed B-cell lines, and Burkitt lymphoma cell lines. All samples from 13 CLL patients and eight of nine B-cell lymphoma ones tested exhibited an extremely low expression of miRs-143 and -145. The expression levels of miRs-143 and -145 were consistently low in human Burkitt lymphoma cell lines and were inversely associated with the cell proliferation observed in the EBV-transformed B-cell lines. Moreover, the introduction of either precursor or mature miR-143 and -145 into Raji cells resulted in a significant growth inhibition that occurred in a dose-dependent manner and the target gene of miRNA-143 was determined to be ERK5, as previously reported in human colon cancer DLD-1 cells. Taken together, these findings suggest that miRs-143 and -145 may be useful as biomarkers that differentiate B-cell malignant cells from normal cells and contribute to carcinogenesis in B-cell malignancies by a newly defined mechanism. (*Cancer Sci* 2007; 98: 1914–1920)

M icroRNAs are endogenous ~22-nt non-coding RNAs that regulate gene expression by inhibiting the translation of mRNAs in a sequence-specific manner.[1–8] With more than 400 already identified, the human genome may contain up to 1000 miRNAs[8] (http://microrna.sanger.ac.uk/). Up to one-third of human mRNAs are predicted to be miRNA targets.[9] Each miRNA can target more than 200 transcripts directly or indirectly,[10,11] whereas more than one miRNA can converge on a single mRNA target.[9,12–15] Therefore, the potential regulatory circuitry afforded by miRNA is enormous. These findings support the notion that alterations of miRNAs copy number and their regulatory genes highly prevalent in cancer because of genomic aberrations is closely associated with carcinogenesis.

Recent increasing evidence shows that the expression of miRNA genes is deregulated in human cancer.[16–19] Specific over- or underexpression has been shown to correlate with particular tumor types.[20–24] miRNA overexpression can result in downregulation of tumor suppressor genes, whereas their under-expression can lead to oncogene upregulation.[16–19] For example, let-7, downregulated in lung cancer,[25–27] suppresses *Ras*,[26] miR-15 and miR-16, deleted or downregulated in CLL,[28] suppress *BCL2*,[29] miR-17-5p and miR-20a control the balance of cell death and proliferation driven by the proto-oncogene *c-Myc*.[30] Clear evidence indicates that miRNA polycistron miR-17-92 serves as an oncogene in lymphoma,[23] and lung cancer,[31] and that miR-372 and miR-373 are novel oncogenes in testicular germ cell tumors that act by numbing the p53 pathway.[32] Thus, miRNA expression profiles may predict the outcome of disease.[25,27,33]

First, by differential hybridization using a DNA microarray for miRNAs and then by semi-quantitative RT-PCR analysis between tumor and non-tumor tissues, we previously found that miRs-143 and -145, whose genes are located within 1.8 kb of each other in the chromosome 5q32 region, were downregulated in colon cancer,[34] as also reported by Michael *et al.*[35] Furthermore, all of the various kinds of human cancer cell lines tested exhibited an extremely low-expression of miRs-143 and -145, whereas the normal tissues in which they originate showed a good expression of both.[34]

In the present study, we investigated the expression of miRs-143 and -145 in hematopoietic malignancies, and found that the expression levels of both miRs were significantly decreased in B-cell malignancies, thus suggesting that they are good markers for B-cell malignancies, especially for CLL in combination with miRs-15 and -16.[28] Furthermore, the expression levels of miRs-143 and -145 were consistently low in Burkitt lymphoma cell lines and were inversely related to the growth of EBV-transformed cell lines. The transfection experiment of Raji cells with either precursor miR-143 or -145 demonstrated that both miRs negatively contributed to the cell growth.

## Materials and Methods

**Patients and tissue preparation.** All human blood and lymph node samples were obtained from patients who had undergone collection for diagnosis at Nagoya University Hospital and its collaborating hospitals in Nagoya, Aichi Prefecture. Human tonsils were also obtained by tonsilectomy. Informed consent in writing was obtained from each patient. Collection and distribution of the samples were approved by the appropriate Institution Review Board. The patients comprised 13 cases of chronic lymphocytic leukemia (CLL) and nine cases of B-cell lymphoma (8DLBCL, 1MALT). Pathological review and FACS analysis showed B-cell non-Hodgkin lymphoma. PBL from three healthy donors were used as normal controls. Fresh lymphoma biopsy specimens and tonsils obtained by operation were gently minced over a wire mesh screen to obtain a cell suspension, which was then centrifuged over Ficoll-Hypaque (Amersham Biosciences AB, Uppsala, Sweden). CD19+ B-cells from the tonsils were used as control cells. Purity was assessed,

and isolation carried out by FACS. All samples were prepared by gravity centrifugation through Ficoll-Hypaque and then frozen in liquid nitrogen until the experiments could be carried out. Such thawed specimens were used for the extraction of total RNA.

**Cell culture, viability and treatment with 5-Aza-2'-deoxycytidine or tricostatin A.** Human Burkitt cell lines Raji, Daudi, P3, and KHM-10B; and human EBV-transformed cells IC, L11, L22, and L25 were grown in RPMI-1640 medium supplemented with 10% (v/v) heat-inactivated FBS (Sigma, St. Louis, MO, USA) and 2 mM L-glutamine under an atmosphere of 95% air and 5% $CO_2$ at 37°C. The number of viable cells was determined by use of the trypan-blue dye exclusion test. 5-Aza (Sigma) was used for demethylation of DNA and histone. TSA (Sigma), a histone deacetylase inhibitor, was also used to examine the effect of acetylation of histone on miR-143 and -145 expression. The cells were treated with these agents for 18 h at various concentrations.

**Quantitative RT-PCR and genomic PCR.** Total RNA was isolated from the cells by the phenol/guanidium thiocyanate method with DNase I treatment. To determine the expression of miRNAs by semi-quantitative RT-PCR, we measured their levels by using a mirVana™ qRT-PCR miRNA Detection Kit (Ambion, Austin, TX, USA) and mirVana qRT-PCR Primer set (Ambion). Briefly, after reverse transcription of 50 ng of total RNA, cDNA was generated. The PCR reaction consisted of 22 cycles (95°C for 15 s, 60°C for 30 s) after an initial denaturation step (95°C for 3 min). The cycle number was initially determined by quantitative PCR. The PCR primer pairs for miRs-143, -145, and -15a were obtained commercially from Ambion. The PCR products obtained by using such primer pairs were confirmed to be from loci of miRs-143 and -145 by DNA sequencing. U6 was used as a control and was determined in each case. In addition, in order to examine the expression level in detail we also carried out TaqMan® MicroRNA Assays using real-time PCR.[16] The Ct is defined as the fractional cycle number at which the fluorescence passes a fixed threshold. miR-143 and miR145 concentration in each type of cell were measured and were normalized to U6, which was used as an internal control. To determine the level of *ERK5* mRNA we prepared cDNA from the total RNA samples by using a PCR purification kit (Qiagen, Hilden, Germany) and used them for PCR (Takara, Ohtsu, Japan). The primers for *ERK5* were as follows: ERK5-sense-211, 5'-CCTTCGATGTGA-CCTTTGAC-3'; and ERK5-antisense-1418, 5'-TGACACCATTG-ATCTGACCC-3'. To examine the presence of the genomic loci of miRs-143 and -145, we extracted DNA from the cell lines tested and used it for PCR (Takara). The primers for genomic loci of miRs-143 and -145 were as follow: 5q32-sense, 5'-TTGGTCCTGGGTGCTCAAAT-3'; and 5q32-antisense, 5'-AGGAACTCCCAAGCTCAAGT-3'. The primers amplified the DNA fragment including both loci at 5q32. The genomic locus of *GAPDH* was used as an internal control. The PCR reaction consisted of 30 cycles (94°C for 30 s, 57.5°C for 1 min, 72°C for 1 min) after an initial denaturation step (95°C for 1 min). The PCR products were analyzed by electrophoresis on 2% agarose gels.

**Transfection of Raji cells with precursor or mature miR-143 and -145 miRNAs.** Raji cells were seeded in six-well plates at a concentration of 1–2 × 10^5/well on the day before the transfection. The miRs-143 and -145 precursors (20–100 nM/mL; Ambion) and mature miRNAs (20–60 nM/mL) were used for the transfection of the cells, which was achieved by using cationic liposomes (i.e. TransIT-TKO) (Mirus Bio Company, Madison, WI, USA) according to the manufacturer's lipofection protocol. The transfection efficiency was evaluated by the transfection of the cells with a duplex siRNA-FITC (Dharmacon, Lafayette, CO, USA). Non-specific control miRNA (NS, 57% GC content; Ambion) was used as a control for non-specific effects. The sequences of mature miRNA-143 (miRNA-143 m) and -145 (miRNA-145 m) were as follows: UGAGAUGAAGCACU-GUAGCUCA and GUCCAGUUUUCCCAGGAAUCCCUU,

respectively. The effects manifested by the introduction of the precursor or mature miRNAs into the cells were assayed at 36 h after the transfection. At the same time, semi-quantitative RT-PCR was carried out on the cells transfected with the precursors.

**Western blotting.** The cells were homogenized in chilled lysis buffer comprising 10 mM Tris-HCl (pH 7.4), 1% NP-40, 0.1% deoxycholic acid, 0.1% SDS, 150 mM NaCl, 1 mM EDTA, and 1% protease inhibitor cocktail (Sigma) and stood for 30 min on ice. After centrifugation at 16 000g for 20 min at 4°C, the supernatants were collected as protein samples. Protein contents were measured with a DC protein assay kit (Biorad, Hercules, CA, USA). 10 μg of lysate protein for western blotting of ERK5 and c-myc was separated by SDS-PAGE using a 10% polyacrylamide gel and electroblotted onto a PVDF membrane (DuPont, Boston, MA, USA). After blockage of non-specific binding sites for 1 h with 5% non-fat milk in PBS containing 0.1% Tween 20, the membrane was incubated overnight at 4°C with antihuman ERK5 antibody (Cell Signaling Tec. Inc., Beverly, MA, USA), antihuman c-myc antibody (Santa Cruz, Santa Cruz, CA, USA) or with DNMT-1 (Santa Cruz). The membranes were then washed three times with PBS containing 0.1% Tween 20, incubated further with HRP-conjugated sheep antimouse or donkey antirabbit Ig antibody (Amersham Biosciences, Piscataway, NJ, USA) at room temperature, and then washed three times with PBS containing 0.1% Tween 20. The immunoblots were visualized by use of an enhanced chemiluminescence detection kit (New England Biolabs, Beverly, MA, USA).

**Statistics.** Differences were statistically evaluated by one-way ANOVA followed by Fisher's PLSD. A *P*-value of less than 0.05 was considered to be statistically significant.

## Results

**Expression levels of miRs-143 and -145 were significantly decreased in B-cell malignancies.** We examined the expression of miRs-143 and -145 in the samples from patients with B-cell malignancies by conducting semi-quantitative RT-PCR and TaqMan assays using real-time PCR. Representative bands of expression obtained by the former and the mean values of TaqMan assays from two independent experiments using the latter are presented in Fig. 1. There was no patient with any abnormality of chromosome 5q32, where miRs-143 and -145 are colocalized within a 1.8-kb distance from each other. In TaqMan assays, Ct values of the samples detected by TaqMan probes corresponding to U6, miR-143 and miR-145 are shown in Table 1. Notably, all of the cases of CLL showed an extremely low-expression (Fig. 1a). Among the B-cell lymphomas, all of the samples except Bl-18 exhibited a low level (Fig. 1b). Recent reports by Calin *et al.*[28] demonstrated that the expression levels of mir-15a and -16 from 13q13.4 were decreased in CLLs with an incidence of approximately 68%. However, the incidence of reduced miR-15a expression in our Japanese CLLs was not so high (approximately 54%, Fig. 1a).

**Relationship between the expression levels of miRs-143 and -145 and cell growth.** In order to clarify the relationship between the

**Table 1. The Ct values of U6, miR-143, and miR-145 in real-time PCR using the TaqMan probes.**

| Standard Curve | Ct | |
|---|---|---|
| | Mean ± SD | CV (%) |
| U6 | 27.1 ± 0.12 | 0.4 |
| miR-143 | 31.0 ± 0.12 | 0.4 |
| miR-145 | 28.1 ± 0.08 | 0.3 |

Ct, cycle threshold; CV, coefficient variation; miR, miRNA; SD, standard deviation.

Akao *et al.*

expression levels of miRs-143 and 145 and cell growth in B-cell lines, we examined the expression levels of EBV-transformed B-cell lines from healthy donors (IC, L11, L22, and L25) and established Burkitt cell lines (Raji, Daudi, P32, and KHM-10B; Fig. 2a). It should be noted that the expression levels were inversely related to the cell growth of EBV-transformed cells from the data of semi-quantitative RT-PCR (Ambion) (Fig. 2a,b; expression level, L25 < L22 = L11 < IC; growth, IC < L22 < L11 < L25). Furthermore, all of the Burkitt cell lines, in which cells have genetic aberrations including c-Myc, showed a fairly low level of the expression of both miRNAs like the L25 cells (Fig. 2a), which showed the highest cell proliferation among the EBV-transformed B-cell lines (Fig. 2b). The data in Fig. 2a,b clearly indicate an inverse

relationship between the expression levels of miR-143 and -145 and cell growth.

**Transfection of RAJI cells with precursor or mature miR-143 or -145, respectively, causes growth inhibition.** In order to examine the suppressive function of miR-143 and -145 with respect to cell growth and to examine which enzymatic modification during miRNA biogenesis is perturbed, we transfected low-expressant Raji cells with precursor miR-143 (miR-143p) or -145 (miR-145p), in which transfection resulted in a significant growth inhibition that occurred in a dose-dependent manner (Fig. 3a). Semi-quantitative RT-PCR using the primers for miR-143 or -145 demonstrated a significant increase in the levels of miR-143 and 145 in the Raji cells transfected with the respective precursors compared with their levels in the control cells

**Fig. 2.** Expression of microRNAs (miRNAs)-143 and -145 and cell growth in B-cell cultured cell lines. (a) Evaluation of expression of miRNAs-143 and -145 in human Epstein-Barr virus (EBV)-transformed B-cell lines and Burkitt lymphoma cell lines by use of semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) and TaqMan MicroRNA assays using real-time PCR. U6 was used as an internal standard. CD19⁺ B-cell-1 was designated as 1 in quantitative RT-PCR by TaqMan miRNA assays using real-time PCR. The results of real-time PCR were expressed as the mean values of two independent experiments. (b) Steady-state cell growth of EBV-transformed B-cell lines at 72 h after seeding at the concentration of 1 × 10⁵/mL (c) Western blot analysis of ERK5 and c-myc in control and B-cell lines in the same samples as in (b), and in human Burkitt lymphoma cell lines. β-actin was used as an internal control.

(Fig. 3a). In order to further confirm that miR-143 or -145 has a growth inhibition, we carried out a transfection experiment using mature miR-143 (miR-143 m) or -145 (miR-145 m) (Fig. 3b). In both experiments, a dose-dependent growth inhibition by the introduction of mature miR-143 or -145, which results were very similar to those obtained when the transfection was carried out with precursor miR-143 or -145. These findings indicate that miR-143 and -145 negatively contribute to cell growth, because the compensation of miR-143 or -145 by the transfection induced growth inhibition and that the perturbation of processing of miR-143 or -145 in the nucleus including transcription and microprocessor of Drosha and DG8 could cause the cells to reduce their expression of both.

**Genomic status and epigenetic change in miR-143 and -145 loci on 5q32.** In order to examine the chromosomal aberrations of miRs-143 and -145 loci on 5q32, we carried out genomic PCR on the B-cell lines by using a primer pair covering both loci.[34] As shown in Fig. 4a, more than one allele was confirmed to be present in all EBV-transformed and Burkitt lymphoma cell lines, as in the placenta, used as the positive control. Furthermore, the treatment with 2–10 µM 5-Aza, which completely reduced the level of DNMT-1, did not upregulate the expression of miRNAs-143 and -145 at all in L25 cells (Fig. 4b); nor did that with TSA.

Thus, it appears that some genomic aberration or epigenetic change did not cause the low expression of miR-143 and -145 in the cells.

**MicroRNA-143 targets the *ERK-5* mRNAs.** Previously, we determined that one of the target genes of miR-143 was *ERK5* in the human colon cancer cell line DLD-1.[34] ERK5 is a recently characterized MAPK, which is most similar to the well-studied ERK1/2 subfamily, but uses distinct mechanisms to elicit responses. The physiological importance of this signaling cascade is underscored by the early embryonic death caused by the targeted deletion of the *erk5* or the *mek5* genes in mice.[36] In Fig. 2c, the level of ERK5 expression in Burkitt lymphoma cell lines was approximately several times higher than that in the other B-cells including CD19⁺ B-cells and EBV transformed B-cell lines except L25, where the pattern was very similar to that of c-myc. We clearly demonstrated that the expression levels between miR-143 and ERK5 were inversely correlated in regard to cell growth in EBV-transformed cell lines (Fig. 2). Based on these results, ERK-5 was shown to be a growth-related MAPK even in B-cells. In order to further confirm that the target mRNA of miR-143 is *ERK5*, we examined the expression of ERK5 and the mRNA in the RAJI cells transfected with precursor miR-143 (Fig. 3). Expectedly the protein expression levels were significantly decreased in a dose-dependent

**Fig. 3.** Effect of transfection of human Burkitt lymphoma Raji cells with either precursor (a) or mature type (b) of microRNAs (miRNAs)-143 and -145, and ERK5 expression in the cells transfected with the precursor miR-143 (c). (a, b) Number of viable transfected or control cells at 36 h after transfection is shown. Data are presented as the mean ± standard deviation (SD) of three different experiments, each carried out in duplicate. Levels of miRNAs-143 and -145 in Raji cells at 36 h after the transfection of the cells with miR-143 or -145 precursor miRNAs at 100 nM are shown in (a). U6 was used as an internal standard. The difference between the non-specific control and 100 (a) or 60 (b) nM treatment was significant ($*P < 0.01$). (c) Expression levels of ERK5 protein and the mRNA at 36 h after the transfection of Raji cells with miR-143 precursor miRNAs, as evaluated by western blot analysis (upper panel) and by quantitative RT-PCR (lower panel), respectively. β-actin was used as an internal standard. Control cells were incubated in medium containing transfection reagent alone.

manner, whereas the mRNA levels were almost unchanged (Fig. 3c). Thus, these findings and the previous results in colon cancer[34] altogether indicate that miR-143 could target the *ERK5* gene even in B-cells.

## Discussion

In the current study, we demonstrated that the expression levels of miRs-143 and -145 were significantly reduced in the B-cell

**1918**

**Fig. 4.** Confirmation of the presence of the genomic loci of microRNAs (miRNAs)-143 and -145 at chromosome 5q32 by genomic polymerase chain reaction (PCR) (a) and expression of the miRNAs in Epstein-Barr virus (EBV)-transformed L25 cells after 24-h treatment with 5-Aza-2'-deoxycytidine (5-Aza, b) or tricostatin A (TSA, c). (a) The primers amplified the DNA fragment including the loci of miRs-143 and -145. Placental DNA was used as a positive control. The genomic locus of glyceraldehyde phosphate dehydrogenase (GAPDH) was used as an internal control. (b, c) The expression of the miRNAs in L25 cells after the treatment with either agent at the indicated concentrations is shown. The value for the control cells is designated as 1 in quantitative reverse transcription (RT)-PCR by TaqMan miRNA assays using a real-time PCR. The results of real-time PCR are expressed as the mean values of two independent experiments. U6 was used as an internal standard. Results of Western blot analysis of DNA methyltransferase (DNMT)-1 are also given in (b).

malignancies tested and further that the expression levels were inversely related to the cell growth in the EBV-transformed B-cell lines, which have no genomic aberrations. The introduction of miR-143 or -145 precursors or mature types into the Raji cells led to a significant growth inhibition. Such data suggest that miRs-143 and -145 could negatively contribute to cell growth by targeting growth-related genes.

The increased expression of miR-143 by the transfection with precursor miR-143 into Raji cells lowered the protein expression levels of ERK5, whereas the mRNA level of *ERK5* remained unchanged, which suggests that *ERK5* is one of the target genes of miR-143, as shown in previous reports by us,[34] and Esau et al.[37]

Recent studies indicate that proteins involved in miRNA biogenesis, including Drosha and double-stranded-RNA-binding protein DGCR8, Dicer 1, Argonaute 2, and RISC, may also participate in the complex interactions that regulate miRNA expression, together with additional mechanisms that regulate miRNA at the epigenetic, transcriptional level. Since the transfection of Raji cells with the precursor miR-143 or -145 exhibited growth inhibition, transcription and/or processing by Drosha and DGCR8 microprocessor in the nucleus was possibly perturbed, which is true in the case of human colon cancer DLD-1 cells.[34] Furthermore, we did not obtain any data that indicated an inappropriate expression caused by genomic aberration or epigenetic change such as methylated DNA and histone. Recently, miR-223 was shown to be upregulated by the retinoic acid-induced replacement of NFI-A with C/EBP α, resulting in promotion of human granulocyte differentiation.[38] As miR-223 repressed NFI-A

translation, the upregulation of miR-223 by C/EBP α and granulopoiesis was further accelerated through positive feedback. Therefore, the machinery involved in the transcription step of miRs-143 and -145, whose primary miRNAs are most likely identical, because their genomic loci are located within a 1.8-kb span, should be clarified for achieving a fully comprehensive view of the processes operating in carcinogenesis.

Rescued expression of downregulated or functionally-deficient miRNAs and/or inhibitors of overexpressed miRNAs may contribute to rebalanced the expression of large gene clusters implicated in oncogenesis, tumor progression, and cell death. One of the target genes for miR-143 was presently shown to be *ERK5* MAPK, which was also shown to be targeted in DLD-1 cells by us,[34] and in adipocytes by others.[37] Also, we suggest that miR-145 may target *MAP3K3* and *MAPK4K4* and that other potential targets for miR-145, which have oncogenic functions, are *MYCN*, *FOS*, *YES*, and *FLI* (http://microrna.sanger.ac.uk/) and cell-cycle promoters such as *cyclin D2* and *L1*. Particularly, the MAPK signal via ERK5 contains c-myc in the downstream of ERK5.[39] Thus, the reduced expression of both miRNAs directly or indirectly affects cell fate such as growth, survival, and death signals; that is, low-expression of miR-143 and -145 possibly by perturbed transcription and/or microprocessing, could result in an unbalanced signaling cascade including MAPK, which would lead to a sustained cell proliferation.

To our knowledge, upregulation of mir-155 from BIC RNA in B-cell lymphomas,[40] and downregulation of miR-14 and -15, which originated from the deletion of a region of chromosome

- 224 -

13q13.4,[28] have been reported in B-cell malignancies. Furthermore, the target gene of miR-15 and -16 was shown to be the antiapoptotic gene BCL-2.[29] Therefore, the genomic deletion of 13q13.4 causes an inappropriate expression of miR-15 and -16 that targets antiapoptotic BCL-2 mRNAs, which negatively works against cell death. We found that the level of miR-15a was reduced in seven of 13 CLLs; however, the level of decrease was not as great as in the case of miRNAs-143 or -145. Our results suggested that the incidence of the 13q13.4 deletion in Japanese CLLs may be lower than that in Caucasian CLLs.[28] Recently, the same group also evaluated the miRNA expression profiles of 41 samples of CLL, and found 25 genes (of 161 analyzed) to have a unique miRNA expression signature.[41] However, miR-143 or -145 was not found to be significant with respect to the miRNA expression profile, although it is not clear whether miR-143 and -145 were examined. Previously, we reported that the expression of miRs-143 and 145 was strongly related to tumorigenesis in colon cancer,[34] because more than 80% of the cases were shown to have low-expression compared

with non-cancerous tissues. In addition, all of the malignant cell lines tested were shown to be downregulated for these miRs.[34]

Thus, miRs-143 and -145 play pivotal roles in the pathogenesis of B-cell malignancies and could be plausible biomarkers to differentiate B-cell malignant cells from normal B-cells, being even better ones than miRs-15a and -16 in Japanese CLLs. Also, we propose miR-143 or -145 as a candidate for the development of RNA medicine against cancer. Further detailed study to decipher the transcription machinery of miR-143 and -145 including their promoter region on 5q32 and their binding sites in the 3′ UTR of ERK5 will be needed for a better understanding of the carcinogenesis involving miRNAs.

## Acknowledgments

## References

1 Lee RC, Feinbaum RL, Ambros V. The *C. elegans* heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. *Cell* 1993; 75: 843–54.

2 Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Incorporating structure to predict microRNA targets. *Science* 2001; 294: 853–8.

3 Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. *Science* 2001; 294: 858–62.

4 Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. *Science* 2001; 294: 862–4.

5 Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* 2004; 116: 281–97.

6 Ambros V. The functions of animal microRNAs. *Nature* 2004; 431: 350–5.

7 He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. *Nat Rev Genet* 2004; 5: 522–31.

8 Zamore PD, Haley B. Ribo-gnome: the big world of small RNAs. *Science* 2005; 309: 1519–24.

9 Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell* 2005; 120: 15–20.

10 Bartel DP, Chen CZ. Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. *Nat Rev Genet* 2004; 5: 396–400.

11 Lim LP, Lau NC, Garrett-Engele P *et al*. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. *Nature* 2005; 433: 769–73.

12 Lewis BP, Shih IH, Jones-Rhoades MW *et al*. Prediction of mammalian microRNA targets. *Cell* 2003; 115: 787–98.

13 John B, Enright AJ, Aravin A *et al*. Human MicroRNA targets. *PLoS Biol* 2004; 2: e363.

14 Kiriakidou M, Nelson PT, Kouranov A *et al*. A combined computational-experimental approach predicts human microRNA targets. *Genes Dev* 2004; 18: 1165–78.

15 Krek A, Grun D, Poy MN *et al*. Combinatorial microRNA target predictions. *Nat Genet* 2005; 37: 495–500.

16 Croce CM, Calin GA. miRNAs, cancer, and stem cell division. *Cell* 2005; 122: 6–7.

17 Gregory RI, Shiekhattar R. MicroRNA biogenesis and cancer. *Cancer Res* 2005; 65: 3509–12.

18 Calin GA, Sevignani C, Dumitru CD *et al*. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. *Proc Natl Acad Sci USA* 2004; 101: 2999–3004.

19 McManus MT. MicroRNAs and cancer. *Semin Cancer Biol* 2003; 13: 253–8.

20 Lu J, Getz G, Miska EA *et al*. MicroRNA expression profiles classify human cancers. *Nature* 2005; 435: 834–8.

21 Volinia S, Calin GA, Liu C-G *et al*. A microRNA expression signature of human solid tumors defines cancer gene targets. *Proc Natl Acad Sci USA* 2006; 103: 2257–61.

22 Calin GA, Liu C-G, Sevignani C *et al*. A microRNA expression signature of human solid tumors defines cancer gene targets. *Proc Natl Acad Sci USA* 2004; 101: 11755–60.

23 He L, Thomson JM, Hemann MT *et al*. A microRNA expression signature of human solid tumors defines cancer gene targets. *Nature* 2005; 435: 828–33.

24 Cummins JM, He Y, Leary RJ *et al*. The colorectal microRNAome. *Proc Natl Acad Sci USA* 2006; 103: 3687–92.

25 Takamizawa J, Konishi H, Yanagisawa K *et al*. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. *Cancer Res* 2004; 64: 3753–6.

26 Johnson SM, Grosshans H, Shingara J *et al*. RAS is regulated by the let-7 microRNA family. *Cell* 2005; 120: 635–47.

27 Yanaihara N, Caplen N, Bowman E *et al*. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. *Cancer Cell* 2006; 9: 189–98.

28 Calin GA, Dumitru CD, Shimizu M *et al*. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. *Proc Natl Acad Sci USA* 2002; 99: 15524–9.

29 Cimmino A, Calin GA, Fabbri M *et al*. miR-15 and miR-16 induce apoptosis by targeting BCL2. *Proc Natl Acad Sci USA* 2005; 102: 13944–9.

30 O'Donnell KA, Wentzel EA, Zeller KI *et al*. c-Myc-regulated microRNAs modulate E2F1 expression. *Nature* 2005; 435: 839–43.

31 Hayashita Y, Osada H, Tatematsu Y *et al*. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. *Cancer Res* 2005; 65: 9628–32.

32 Voorhoeve PM, le Sage C, Schrier M *et al*. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. *Cell* 2006; 124: 1169–81.

33 Calin GA, Ferracin M, Cimmino A *et al*. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. *N Engl J Med* 2005; 353: 1793–801.

34 Akao Y, Nakagawa Y, Naoe T. MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. *Oncol Reports* 2006; 16: 845–50.

35 Michael MZ, O'Connor SM, van Holst Pellekaan NG *et al*. Reduced accumulation of specific microRNAs in colorectal neoplasia. *Mol Cancer Res* 2003; 1: 882–91.

36 Nishimoto S, Nishida E. MAPK signalling: ERK5 versus ERK1/2. *EMBO Rep Rev* 2006; 7: 782–6.

37 Esau C, Kang X, Peralta E *et al*. MicroRNA-143 regulates adipocyte differentiation. *J Biol Chem* 2004; 279: 52361–5.

38 Fazi F, Rosa A, Fatica A *et al*. A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPα regulates human granulopoiesis. *Cell* 2005; 123: 819–31.

39 English JM, Pearson G, Baer R *et al*. Identification of substrates and regulators of the mitogen-activated protein kinase ERK5 using chimeric protein kinases. *J Biol Chem* 1998; 273: 3854–60.

40 Eis PS, Tam W, Sun L *et al*. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. *Proc Natl Acad Sci USA* 2005; 102: 3627–32.

41 Calin GA, Liu CG, Sevignani C *et al*. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. *Proc Natl Acad Sci USA* 2004; 101: 11755–60.

● 悪性リンパ腫

# 濾胞性リンパ腫に対する治療の進歩

名古屋大学大学院医学系研究科 血液・腫瘍内科学 准教授

## 木 下 朝 博

**要 旨**　濾胞性リンパ腫はこれまで化学療法などの効果が不十分で難治性リンパ腫とされてきた．近年抗 CD20 モノクローナル抗体や放射性同位元素標識モノクローナル抗体，プリンアナログなどといった新規薬剤の開発が進み，治療成績が改善しつつある．また，リツキシマブによる *in vivo* purging を応用した自己造血幹細胞移植や骨髄非破壊的同種造血幹細胞移植などの新しい移植法が開発されている．

## は じ め に

　濾胞性リンパ腫（FL）は代表的な低悪性度リンパ腫病型であり，経過が緩慢で進行期でも生存期間中央値は 7 ～ 10 年と長い．しかし，化学療法の効果が不良で多くは組織学的進展（histologic transformation）などによって最終的に死亡する難治性疾患であり，長期予後は中・高悪性度リンパ腫よりもむしろ悪い．ただし，多くの新規治療法が開発導入されていることや支持療法が進歩しているため予後が改善しつつある[1]．本稿では近年著しく進歩した FL に対する治療について，進展期に対する治療を中心に解説する．

---

キーワード：濾胞性リンパ腫，化学療法，モノクローナル抗体，
　　　　　　リツキシマブ，放射線免疫療法

## 薬　物　療　法

### 1．無治療での経過観察―watchful waiting

　これまで FL は化学療法による治癒が困難なことや病状の進行が緩徐であるため；無症状，高齢者，腫瘍量が少ない，予後不良因子を有しない，合併症を有する場合には，病状が進展したり症状が出現したりするまで無治療で経過観察を行う（watchful waiting）ことも診療方針の1つとされてきた[2]．現在でも watchful waiting は診療方針の1つとなりうるが，近年，後述するようなさまざまな新規治療法が開発されているため，より積極的に治療を開始することが多くなっていると推定される．

### 2．化　学　療　法

　FL に対する化学療法としてはシクロホスファミドなどのアルキル化剤，多剤併用療法 [COP ないし CVP（シクロホスファミド，ビンクリスチン，プレドニゾロン）療法や CHOP（シクロホスファミド，ドキソルビシン，ビンクリスチン，プレドニゾロン）療法など]，プリンアナログ（フルダラビン，クラドリビンなど）などがある．しかし，進展期 FL に治癒をもたらしたり生存期間を延長したりすることが証明された化学療法はない．

　プリンアナログのうちフルダラビンは慢性リンパ性白血病に対して広く使用されており，クラドリビンは有毛細胞白血病（hairy cell leukemia）に対する標準的治療薬と位置づけられている．これらの薬剤は FL を始めとする低悪性度リンパ腫にも広く用いられている．FL に対するフルダラビン単剤療法では完全寛解（CR）37％，奏効率 65％ が得られた[3]．また，フルダラビンはシクロホスファミドやデキサメタゾン，ミトキサントロンなどとの併用療法も行われており，良好な奏効率が報告されている[4]．クラドリビンも低悪性度リンパ腫に対して有効な薬剤であり，高い奏効率を示す[5]．

　現在ではこれらの化学療法は後述する抗 CD20 モノクローナル抗体リツキシマブと併用されることが多く，優れた治療成績が報告されている．

図1 抗 CD20 モノクローナル抗体，リツキシマブの構造



略語：巻末の「今号の略語」参照

### 3．抗 CD20 モノクローナル抗体，リツキシマブ

　マウス・ヒトキメラ型抗 CD20 モノクローナル抗体であるリツキシマブはB細胞表面の分化抗原である CD20 を標的とする薬剤であり，B細胞リンパ腫に対して高い治療効果を示す（図1）．再発・再燃低悪性度B細胞リンパ腫を対象として行われた単剤投与試験では，CR 6 ％，部分寛解（PR）42 ％ で奏効率は 48 ％，効果持続期間の中央値は 13 ヵ月だった[6]．

　一般的に FL ではポリメラーゼ連鎖反応（PCR）レベルで検出される微少残存病変（MRD）を通常化学療法で消失させることは困難とされる．これに対してリツキシマブは MRD レベルでみた場合にも高い治療効果を示す．単剤での治療の場合，FL で 22 ～ 62 ％ に MRD 消失が得られる[7]．

### 4．リツキシマブと化学療法の併用

　リツキシマブは通常の化学療法剤と有害反応が重複しないことから化学療法への併用が可能である．FL を中心とする低悪性度Bリンパ腫に対して，CHOP 療法との併用により CR 55 ％，奏効率 95 ％ という極めて良好な治療効果が報告された（図2）[8]．

　リツキシマブ併用化学療法は併用しない化学療法よりも良好な治療成績を示す．未治療進展期 FL を対象としてリツキシマブ併用 CVP

図2　R-CHOP療法による低悪性度B細胞リンパ腫の無増悪生存期間（未治療患者と既治療患者のデータ）

（文献[8]より引用改変）



その他のグラフ：
(%) 無増悪生存率 縦軸 / 無増悪生存期間 (月) 横軸

-×- 未治療患者（n＝29）
-○- 既治療患者（n＝9）

（シクロホスファミド，ビンクリスチン，プレドニゾロン）（R-CVP）療法をCVP療法と比較する試験が行われ，全奏効率およびCR率，無増悪生存期間すべてでR-CVPがCVPに対して勝った（図3）[9]．シクロホスファミド，フルダラビン，ミトキサントロン（FCM）療法とリツキシマブの併用療法についてもFCM療法との無作為化比較試験が行われ，R-FCMがFCMに対してCR率や全奏効率で有意に勝っていた[10]．このようにリツキシマブ併用化学療法はFLに対して高い治療効果を示すことから，リツキシマブ併用化学療法がFLに対する標準的治療と位置づけられつつある．

　その他のリツキシマブ併用化学療法としてはプリンアナログとの併用の試みがあり，例えばフルダラビンとの併用ではCR 80％を含む奏効率90％，およびMRD消失効果が88％に得られた[11]．

## 5．リツキシマブ維持療法

　リツキシマブによる維持療法もFLに対する重要な治療法の1つである．再発・再燃FLに対するCHOPまたはR-CHOP治療後のリツキシマブ維持療法に関する検討では，CHOPまたはR-CHOPい

図3　未治療進展期濾胞性リンパ腫（FL）に対する R−CVP 療法と CVP 療法の比較試験における
　　　無増悪生存期間（文献[9]より引用改変）



ずれで治療された FL においてもリツキシマブ維持療法によって無増
悪生存期間，全生存期間の改善が認められた[12]．今後我が国において
もリツキシマブ維持療法の承認が期待される．

## 6．放射性同位元素標識モノクローナル抗体

　リンパ腫細胞は放射線治療に対する感受性が高いため，アイソトー
プ抱合モノクローナル抗体（radioimmunoconjugates；RIC）の開発
が進められた．RIC は抗体が直接結合できなかった近接細胞に対し
てもクロスファイアー効果によって放射線治療効果を発現する．
CD20 を標的とするものとしては，yttrium − 90（$^{90}$Y）ibritumomab
tiuxetan[13]，iodine − 131（$^{131}$I）tositumomab[14] がある．未治療進展期
FL に対する $^{131}$I tositumomab 治療では，CR 75 %，全奏効率は 95 %
で，CR 例の 80 % は PCR レベルの MRD も陰性化した[15]．5 年無増
悪生存率と全生存率はそれぞれ 59 % と 89 %，無増悪生存期間の中
央値は 6.1 年と極めて良好だった（図4）．また，未治療 FL を対象
として，CHOP 療法に引き続いて $^{131}$I tositumomab を投与する第 II 相
試験が行われ，CR 率は 69 %，5 年全生存率と無増悪生存率はそれぞ
れ 87 % と 67 % と極めて良好だった[16]．

図4　未治療進展期濾胞性リンパ腫（FL）に対する $^{131}$I tositumomab 治療の無病
生存曲線および全生存曲線（文献[15]より引用改変）



　　このように RIC は FL に対して高い有効性を示す新規薬剤であり，移植前処置への応用も含め，今後 FL 治療において大きな役割を果たすことが期待される．

### 7．造血幹細胞移植

#### 1）自己造血幹細胞移植併用大量化学療法

　　FL は通常化学療法による治癒が困難な難治性疾患であることから，自己造血幹細胞移植（AHSCT）を併用した大量放射線化学療法が盛んに研究されてきた．FL では高率に骨髄浸潤を認めるため移植片中のリンパ腫細胞を除去することが重要である．現在では *ex vivo* purging に代わりリツキシマブを用いた *in vivo* purging が広く応用されている[17]．

　　初発進行期 FL に対する upfront AHSCT の有用性に関する比較試験は少ない．未治療 FL を対象とした AHSCT とインターフェロンによる維持療法の無作為化比較試験では，5 年無増悪生存率では移植群がインターフェロン群に勝った．しかし，生存期間についてはデータが未公表である[18]．また，再発・治療抵抗性 FL を対象とした通常化学療法と AHSCT の比較試験では，化学療法群に比べて AHSCT

群で無増悪生存期間が有意に良好だったが生存期間には有意差を認め
なかった[19].

　近年リツキシマブに代表される新規薬剤の導入によって FL の治療
成績が向上しつつあることや，AHSCT に伴う二次発がん，特に骨髄
異形成症候群が問題となることなどから，FL に対して実地医療とし
て早期に AHSCT を行うべきではないと考えられている．今後 AH-
SCT の適応や移植時期についての検討が必要である．

2） 同種造血幹細胞移植

　一般的には同種造血細胞移植は AHSCT 後の再発症例を対象に行
われる場合が多く，移植片対白血病（GVL）効果によって FL に対
して治癒が期待できる治療と言えるが，一方，治療関連死亡率が 30
～ 40 ％ と高いことが問題である．近年，移植前処置の毒性を軽減し
た骨髄非破壊的同種造血幹細胞移植（RIST）が盛んに試みられてお
り，少数例ながら有望な治療成績が報告されている[20].

## お わ り に

　このように FL に対してはリツキシマブに代表される有効な新規薬
剤の開発が進んでおり，高い治療効果が得られている．今後これら薬
剤や造血細胞移植療法を効果的に組み合わせた治療戦略を確立する必
要がある．

## 文　　　　献

1) Swenson W T, et al: Improved survival of follicular lymphoma patients in
   the United States.　J Clin Oncol **23** (22): 5019–5026, 2005.

2) Horning S J, et al: The natural history of initially untreated low–grade non-
   Hodgkin's lymphomas.　N Engl J Med **311** (23): 1471–1475, 1984.

3) Solal–Celigny P, et al: Phase II trial of fludarabine monophosphate as first-
   line treatment in patients with advanced follicular lymphoma: a multicenter
   study by the Groupe d'Etude des Lymphomes de l'Adulte.　J Clin Oncol
   **14** (2): 514–519, 1996.

4) Hochster H S, et al: Phase I study of fludarabine plus cyclophosphamide in
   patients with previously untreated low–grade lymphoma: results and and
   long–term follow–up—a report from the Eastern Cooperative Oncology
   Group.　J Clin Oncol **18** (5): 987–994, 2000.

5) Saven A, et al: 2–Chlorodeoxyadenosine activity in patients with untreated,

　　　indolent non–Hodgkin's lymphoma.　Blood **86** (5): 1710–1716, 1995.

6) McLaughlin P, et al: Rituximab chimeric anti–CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.　J Clin Oncol **16** (8): 2825–2833, 1998.

7) Foran J M, et al: A UK multicentre phase II study of rituximab (chimaeric anti–CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response.　Br J Haematol **109** (1): 81–88, 2000.

8) Czuczman M S, et al: Treatment of patients with low–grade B–cell lymphoma with the combination of chimeric anti–CD20 monoclonal antibody and CHOP chemotherapy.　J Clin Oncol **17** (1): 268–276, 1999.

9) Marcus R, et al: CVP chemotherapy plus rituximab compared with CVP as first–line treatment for advanced follicular lymphoma.　Blood **105** (4): 1417–1423, 2005.

10) Forstpointner R, et al: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low–Grade Lymphoma Study Group.　Blood **104** (10): 3064–3071, 2004.

11) Czuczman M S, et al: Rituximab in combination with fludarabine chemotherapy in low–grade or follicular lymphoma.　J Clin Oncol **23** (4): 694–704, 2005.

12) van Oers M H, et al: Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non–Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.　Blood **108** (10): 3295–3301, 2006.

13) Witzig T E, et al: Phase I/II trial of IDEC–Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20 (+) B–cell non–Hodgkin's lymphoma.　J Clin Oncol **17** (12): 3793–3803, 1999.

14) Kaminski M S, et al: Iodine–131–anti–B1 radioimmunotherapy for B–cell lymphoma.　J Clin Oncol **14** (7): 1974–1981, 1996.

15) Kaminski M S, et al: 131I–tositumomab therapy as initial treatment for follicular lymphoma.　N Engl J Med **352** (5): 441–449, 2005.

16) Press O W, et al: Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I–131 tositumomab for previously untreated follicular non–Hodgkin's lymphoma: five–year follow–up of Southwest Oncology Group Protocol S9911.　J Clin Oncol **24** (25): 4143–4149, 2006.

17) Magni M, et al: Successful in vivo purging of CD34–containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion.　Blood **96** (3): 864–869, 2000.

18) Lenz G, et al: Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression–free survival in follicular lymphoma: results of a prospective, randomized trial of

the German Low–Grade Lymphoma Study Group. Blood **104** (9): 2667–2674, 2004.

19) Schouten H C, et al: High–dose therapy improves progression–free survival and survival in relapsed follicular non–Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol **21** (21): 3918–3927, 2003.

20) Khouri I F, et al: Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft–versus–host disease, and treatment–related mortality. Blood **98** (13): 3595–3599, 2001.

# Progress in the Treatment for Follicular Lymphoma

Tomohiro Kinoshita

Department of Hematology and Oncology Nagoya University
Graduate School of Medicine

**特集**　｜　抗CD20抗体臨床導入後のB細胞リンパ腫治療：現状と将来展望

# リツキシマブ導入後のびまん性大細胞型B細胞リンパ腫患者の予後推定と至適治療*

木　下　朝　博**
平　賀　潤　二**
大　野　稔　人**

---

**Key Words** : diffuse large B-cell lymphoma, rituximab, R-CHOP, prognostic factors

---

## は じ め に

Diffuse large B-cell lymphoma(DLBCL)はいわゆるaggressive lymphomaの主要な部分を占める, わが国ではもっとも頻度が高い悪性リンパ腫病型である. これまではCHOP(cyclophosphamide, doxorubicin, vincristine, prednisolone)療法が標準的化学療法として位置づけられてきた. しかし近年, 抗CD20モノクローナル抗体薬剤, rituximabが開発され, rituximab併用CHOP(R-CHOP)療法がDLBCLに対する標準的治療として確立した.

DLBCLではさまざまな臨床的, 生物学的な予後因子や予後予測モデルが提唱されている. なかでもInternational Prognostic Index(IPI)は臨床研究での患者選択基準や実地臨床での治療選択に広く用いられている. またDNAマイクロアレイを用いた遺伝子発現プロフィール解析によって同定されたDLBCL亜型が免疫組織学的方法でも同定可能となり, DLBCL研究に新たな局面を開きつつある.

本稿ではDLBCLに対する治療の現況について概観するとともに, R-CHOP時代におけるDLBCLの予後予測とその将来的な課題について考察したい.

## DLBCLに対する標準的治療としてのR-CHOPの確立

マウス・ヒトキメラ型抗CD20モノクローナル抗体であるrituximabはB細胞表面抗原であるCD20を標的とする薬剤であり, B細胞リンパ腫に対して高い治療効果を示す. Rituximabは主にcomplement-dependent cytotoxicity(CDC；補体依存細胞傷害反応)やantibody-dependent cellular cytotoxicity(ADCC；抗体依存性細胞傷害反応)といった機構によってCD20陽性細胞を傷害する. このほかに免疫反応を介さずapoptosisを誘導することもその作用機序とされる. Rituximabは通常の化学療法剤と薬物有害反応が重複しないために化学療法への併用が可能である.

R-CHOP療法はもっとも代表的なrituximab併用化学療法である. DLBCLに対するR-CHOPの有用性を検証する複数の大規模臨床試験が施行された. GELAでは未治療高齢者DLBCLを対象としたR-CHOPとCHOPの無作為化比較試験が実施され, event free survival(EFS), overall survival(OS), 完全奏効(complete response；CR)率すべてでR-CHOPがCHOPに勝った(図1)[1)2)].

米国でも未治療高齢者DLBCLを対象としたR-CHOPとCHOPの比較試験(E4494)が施行された. 本試験はR-CHOPまたはCHOPでCRまたはpartial

---